Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2024 Earnings Call Transcript

Steve Mahoney: Yes. In our deck, you can see that we’ve got some healthy volunteer data that’s pegged to the second half of 2025 for that 006 program. It’s a little ways out. So we’ll look to see if we can pull that timeline in, but we feel, we’re on track for that IND. And then we’ll get the healthy volunteer study going. And so we’ll get some data there. I think don’t forget the 008 non-human primate data that has in other FcRns that has proven to be pretty translatable. So we’re pretty excited to see that. We saw great humanized mice data for 008, but obviously that’s mice data. We want to see the NHPs. We’ll get that in the second half of this year. So we think that’s actually a relatively important thing for us to get. So we’re looking forward to FcRn moving forward. We got a lot to do there.

Trevor Allred: Okay. Great. Thanks, Steve.

Steve Mahoney: Great. Thank you.

Operator: At this time – sorry, at this time, we have reached the conclusion of the question-and-answer session. I would now like to turn the call back to Viridian’s President and CEO, Steve Mahoney for closing remarks.

Steve Mahoney: Great. Thank you, operator, and thanks to everyone for joining the call this morning. We’ve made a lot of progress and we are executing. We’re delivering on what we’ve said, and that’s important. We know that’s important to you as well. So thank you for your participation today, and we look forward to talking to you in the future.

Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating.